| Vaccine protection against Zika virus from Brazil RA Larocca, P Abbink, JPS Peron, PM de A. Zanotto, MJ Iampietro, ... Nature 536 (7617), 474-478, 2016 | 617 | 2016 |
| Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys P Abbink, RA Larocca, RA De La Barrera, CA Bricault, ET Moseley, ... Science 353 (6304), 1129-1132, 2016 | 575 | 2016 |
| Rapid development of a DNA vaccine for Zika virus KA Dowd, SY Ko, KM Morabito, ES Yang, RS Pelc, CR DeMaso, ... Science 354 (6309), 237-240, 2016 | 441 | 2016 |
| Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine R Edelman, SS Wasserman, SA Bodison, RJ Putnak, KH Eckels, D Tang, ... American Journal of Tropical Medicine and Hygiene 69 (6), 48, 2003 | 247 | 2003 |
| An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model JR Putnak, BA Coller, G Voss, DW Vaughn, D Clements, I Peters, ... Vaccine 23 (35), 4442-4452, 2005 | 226 | 2005 |
| Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. BM Kaufman, PL Summers, DR Dubois, KH Eckels The American journal of tropical medicine and hygiene 36 (2), 427-434, 1987 | 215 | 1987 |
| Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo … K Modjarrad, L Lin, SL George, KE Stephenson, KH Eckels, ... The Lancet 391 (10120), 563-571, 2018 | 213 | 2018 |
| Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys R Putnak, DA Barvir, JM Burrous, DR Dubois, VM D'Andrea, CH Hoke, ... Journal of Infectious Diseases 174 (6), 1176-1184, 1996 | 202 | 1996 |
| Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection BM Kaufman, PL Summers, DR Dubois, WH Cohen, MK Gentry, ... Am J Trop Med Hyg 41 (5), 576-580, 1989 | 196 | 1989 |
| Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates W Sun, R Edelman, N Kanesa-Thasan, KH Eckels, JR Putnak, AD King, ... The American journal of tropical medicine and hygiene 69 (6_suppl), 24-31, 2003 | 194 | 2003 |
| Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes T Hase, PL Summers, KH Eckels Archives of virology 104, 129-143, 1989 | 176 | 1989 |
| Production and evaluation of a formalin-killed Chikungunya vaccine VR Harrison, KH Eckels, PJ Bartelloni, C Hampton The Journal of Immunology 107 (3), 643-647, 1971 | 175 | 1971 |
| Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults W Sun, D Cunningham, SS Wasserman, J Perry, JR Putnak, KH Eckels, ... Human vaccines 5 (1), 33-40, 2009 | 168 | 2009 |
| Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children S Simasathien, SJ Thomas, V Watanaveeradej, A Nisalak, C Barberousse, ... The American journal of tropical medicine and hygiene 78 (3), 426-433, 2008 | 150 | 2008 |
| Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus … M Bray, BT Zhao, L Markoff, KH Eckels, RM Chanock, CJ Lai Journal of Virology 63 (6), 2853-2856, 1989 | 150 | 1989 |
| Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis YM Zhang, EP Hayes, TC McCarty, DR Dubois, PL Summers, KH Eckels, ... Journal of Virology 62 (8), 3027-3031, 1988 | 145 | 1988 |
| Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development KH Eckels, WE Brandt, VR Harrison, JM McCown, PK Russell Infection and immunity 14 (5), 1221-1227, 1976 | 140 | 1976 |
| A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness VJ Gunther, R Putnak, KH Eckels, MP Mammen, JM Scherer, A Lyons, ... Vaccine 29 (22), 3895-3904, 2011 | 138 | 2011 |
| Durability and correlates of vaccine protection against Zika virus in rhesus monkeys P Abbink, RA Larocca, K Visitsunthorn, M Boyd, RA De La Barrera, ... Science translational medicine 9 (420), eaao4163, 2017 | 135 | 2017 |
| A purified inactivated Japanese encephalitis virus vaccine made in Vero cells AK Srivastava, JR Putnak, SH Lee, SP Hong, SB Moon, DA Barvir, B Zhao, ... Vaccine 19 (31), 4557-4565, 2001 | 134 | 2001 |
